Institut Pasteur de Lille

What Institut Pasteur de Lille does

Institut Pasteur de Lille is a private, non-profit foundation recognized as a public utility since 1898, headquartered at 1 Rue du Professeur Calmette in Lille, France. Founded in 1894 by Albert Calmette in response to a diphtheria epidemic, the institute is credited with developing the BCG tuberculosis vaccine in 1921 and operates 800+ personnel across 34 research teams organized into 8 specialized research units covering infectious diseases, metabolic diseases (diabetes, obesity), cancer, neurodegenerative diseases (Alzheimer's), cardiovascular diseases, and antibiotic resistance. It hosts a Drug Discovery Center, multiple shared technology platforms (BICeL bioimaging/cytometry, ARIADNE high-content screening, P3M proteomics, NMR, LIGAN MP genomics, Bille bioinformatics, TAG transcriptomics), and incubates biotech startups on campus including Bioversys, StarkAge Therapeutics, Genoscreen, Apteeus, 4P-Pharma, and Immune Insight.

The institute generates revenue across five distinct streams: individual donations and bequests (with 66% tax deduction), institutional research grants from CNRS, INSERM, University of Lille, and European programs, biotech licensing and facility sharing with campus startups, corporate sponsorship, and prevention services. The prevention arm operates a WHO-accredited International Vaccination Center (since 1951), a preventive health checkup center, and a rabies center across four regional locations (Lille, Tourcoing, Arras, Béthune), with appointments managed via Doctolib and Omnidoc. Additional offerings include the Longevity Path preventive medicine program, the Pasteur Institute Museum, the Le 1894 event venue, the Kid Campus science education program for CM1-CM2 students, and the Vipali digital health prevention tool launched in 2023.

The institute is governed by a Board of Directors including representatives from regional institutional partners (European Metropolis of Lille, Hauts-de-France Regional Council, Nord Departmental Council) and is led by Director General Frédéric Batteux (appointed September 2024) and Deputy Director General Perrine Quivron (appointed December 2024). It operates independently but coordinates the Europe region of the International Network of Pasteur Institutes (RIIP), comprising 32 institutes across 25 countries, and maintains active research collaborations with University of Lille, Imperial College London, CNRS, INSERM, and CHU de Lille.

Name

Institut Pasteur de Lille

Legal name

Institut Pasteur de Lille

Website

https://pasteur-lille.fr

Company type

Private

Founded year

1894

Operating status

Operating

Headcount range

101–250 employees

Short description

Institut Pasteur de Lille is a 130-year-old non-profit biomedical research foundation in Lille, France, with 800+ researchers across 8 units conducting research on infectious, metabolic, and neurodegenerative diseases. It generates revenue through donations, research grants, biotech partnerships, prevention services, and corporate sponsorship.

Ownership category

akta.pro rank

Product category

Biomedical Research and Preventive Healthcare Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Health Care and Social Assistance (62), Voluntary Health Organizations (813212), Medical and Diagnostic Laboratories (6215)

SIC

Services-Health Services (8000), Services-Medical Laboratories (8071), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Global Health Research, Evidence & Technical Assistance Organizations (HLAJAKAN)

akta.pro secondary industries

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM), National/State/Local Immunization Program Offices (HLAJAHAA), Chronic Disease Prevention & Health Promotion Departments (HLAJAAAN), Non-Communicable Disease Prevention & Chronic Disease Programs (BPAIAJAI)

Keywords

• Biomedical research services
• Preventive healthcare services
• Vaccine development research
• Clinical investigation trials
• Public health foundation

Headquarters

HQ city

Lille

HQ country

France

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others

Revenue model

1. Donations and charitable contributions: Individual donations, bequests, and legacies from supporters. The institute receives tax-deductible donations with 66% tax reduction for individuals.
2. Biotechnology company partnerships: Revenue from biotech startups hosted on campus including Bioversys, StarkAge Therapeutics, Genoscreen, Apteeus, 4P-Pharma, and Immune Insight through licensing, co-development, and facility sharing arrangements.
3. Prevention and healthcare services: Revenue from vaccination center, health checkups, and preventive medicine services offered to individuals and enterprises
4. Corporate sponsorship and mecenat: Corporate sponsorship programs where companies support research in exchange for association with the institute
5. Institutional research funding: Funding from public institutions including CNRS, INSERM, University of Lille, and European research grants

Pricing tiers

Go-to-market motion1 record

Distribution channels6 records

Marketing channels12 records

Core offering

Institut Pasteur de Lille is a non-profit research foundation that conducts fundamental and applied biomedical research in infectious diseases (notably vaccinology and respiratory pathogens), nutrition/metabolic disorders (diabetes, obesity, cardio-metabolic disease), and neurodegenerative diseases (Alzheimer's and related dementias). It complements this research with a Center for Preventive Medicine that delivers individual health check-ups, a Clinical Investigation Center supporting clinical trials, and the SH2 center for human and social sciences, while also running training programs and public-health outreach actions.

Product overview

Institut Pasteur de Lille is a private, non-profit research foundation recognized as a public utility since 1898, operating as an integrated research and healthcare institution. The organization offers a combination of clinical healthcare services (international vaccination center, preventive health checkups, rabies center), research infrastructure (Drug Discovery Center, technological platforms for genomics, proteomics, bioinformatics, and screening), and public engagement (museum, educational programs like Kid Campus, and the 1894 event venue). The Institute conducts research across 34 teams organized into 8 units, focusing on areas including infectious diseases, cancers, neurodegenerative diseases, cardiovascular and metabolic diseases, and drug discovery. Key digital offerings include Vipali for personalized health prevention. The institution's preventive health programs, including the Longevity Path initiative, represent an innovative approach to predictive and preventive medicine.

Differentiator

Problem solved

Functional benefit

Products and services

• Center for Preventive Medicine (Centre de Prévention Santé) On-site preventive health service that delivers comprehensive individual health check-ups to adults in the Lille region, covering screening and risk assessment for the diseases studied by the foundation. It serves the general adult population seeking preventive screening.
• Clinical Investigation Center (CIC) Hospital-adjacent clinical research platform supporting translational research and clinical trials across the foundation's three thematic priorities. It serves academic and industry research partners requiring clinical study infrastructure.
• Infectious Diseases and Vaccinology Research Program Core research program focused on respiratory pathogens including SARS-CoV-2 and influenza, with deep expertise in vaccinology. It produces scientific knowledge and vaccine candidates intended for the scientific community and public-health stakeholders.
• Nutrition, Diabetes, Obesity and Cardio-Metabolic Disease Research Program Research program investigating the determinants, mechanisms and prevention of nutrition-related metabolic disorders. It generates scientific publications and translational outputs for the research and public-health community.
• Alzheimer's Disease and Neurodegenerative Disease Research Program Research program dedicated to Alzheimer's disease and related dementias, covering pathogenesis, biomarkers, and prevention strategies. Outputs target the scientific, clinical, and public-health communities.
• SH2 Center for Human and Social Sciences Research and analysis center integrating human and social science perspectives into the foundation's biomedical priorities. It serves public-health stakeholders and policy-oriented decision makers needing behavioral and societal insights.
• University and Academic Training Programs Educational programs offered to students and early-career researchers in partnership with universities, covering biomedical and public-health disciplines aligned with the foundation's research themes.
• Public Health Awareness Campaigns and Outreach Public-facing campaigns, events and educational outreach that translate the foundation's scientific findings into health-promoting messages for the general population, with a focus on the diseases studied by the foundation.

Quantifiable outcome

• 91 genetic regions identified associated with Alzheimer's disease risk, including 16 new regions in European populations
• +4 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability3 records

Feature7 records

Partnerships

19 partnerships are on record, tiered core, key and minor.

• International Network of Pasteur Institutes (RIIP)coreStrategic or Co-development Partner · 1 November 2018The Institut Pasteur de Lille coordinates the Europe region within the RIIP since November 2018, a three-year strategic mandate. The network comprises 32 institutes in 25 countries united by the mission of protecting human health through research, training, and disease surveillance.
• University of LillecoreStrategic or Co-development PartnerJoint research collaborations including Unit U1283/8199 'Multi-omics and pathophysiology of metabolic diseases' and multiple other joint research units combining University, CNRS, Inserm, and Institut Pasteur de Lille researchers.
• Imperial College LondoncoreStrategic or Co-development PartnerInternational research collaboration led by Dr. Amna Khamis and Professor Philippe Froguel on pancreatic aging and diabetes research, published in Nature Communications.
• CNRS (National Centre for Scientific Research)coreStrategic or Co-development PartnerJoint research units and collaborative research programs including UMR9017, UMR9031, and multiple other CNRS partnerships on the campus.
• INSERM (National Institute of Health and Medical Research)coreStrategic or Co-development PartnerJoint research units including UMR1011, UMR1167, UMR1177, UMR1190, UMR1283, and collaborative research across metabolic, cardiovascular, and neurodegenerative disease research.
• CHU de Lille (Lille University Hospital)coreStrategic or Co-development PartnerClinical research collaboration and translational research partnership including Joint Research Units U1190 and U1283/8199 focused on diabetes and metabolic diseases.
• Bioversys SASkeyStrategic or Co-development PartnerBiotech subsidiary of Swiss company BioVersys AG focused on developing small molecules targeting bacterial resistance. Uses TRIC technology for antibiotic resistance research. Located on campus with R&D activities in Unit U1177.
• GlaxoSmithKline (GSK)keyStrategic or Co-development PartnerCollaboration with Bioversys on tuberculosis research programs in preclinical development, as part of GSK's involvement in combating hospital-acquired infections.
• StarkAge TherapeuticskeyStrategic or Co-development PartnerPrivate biotechnology startup founded in 2018 focusing on delaying progression of age-related diseases by targeting senescent cell accumulation. Leverages biomarker technology and immunotherapy approaches.
• GenoscreenkeyStrategic or Co-development PartnerFrench biotechnology company created on campus in 2001 specializing in genomics analytics and bioinformatics services. Generates over 80% revenue outside Lille metropolitan area with 30% from exports.
• ApteeuskeyStrategic or Co-development PartnerInnovative company founded in 2013 specializing in personalized medicine for rare and orphan diseases. Uses miniaturized drug discovery techniques from Unit U1177 for patient-specific drug repurposing screening.
• 4P-PharmakeyStrategic or Co-development PartnerClinical-stage biotechnology company launched in 2016 dedicated to developing therapies for serious diseases with unmet medical needs. Led by Dr. Nadira Delhem and Dr. Olivier Moralès.
• Immune InsightkeyStrategic or Co-development PartnerStartup offering preclinical drug safety validation services focusing on immune cells and regulatory T lymphocytes. Method directly derived from Pasteur Institute research with internationally recognized unique services.
• LifebloomminorStrategic or Co-development PartnerMedical device startup founded in 2016 developing physical assistance devices for people with reduced mobility. Incubated at Eurasanté center. Committed to social and solidarity economy principles.
• VipaliminorStrategic or Co-development PartnerDigital health prevention tool developed to support personalized health prevention. Assesses lifestyle habits and provides recommendations on diet, physical activity, sleep, wellbeing, and daily behaviors.
• European Metropolis of Lille (MEL)coreStrategic or Co-development PartnerRegional institutional partner represented on the Board of Directors through Vice-President Arnaud Deslandes for Economy, Research, University and Entrepreneurship.
• Hauts-de-France Regional CouncilcoreStrategic or Co-development PartnerRegional institutional partner represented by Vice-President Manoëlle Martin on the Board of Directors. Supports regional health and research initiatives.
• Nord Departmental CouncilcoreStrategic or Co-development PartnerDepartmental institutional partner represented by Councillor Charlotte Lecocq Parmentier on the Board of Directors.
• Laboratoires AniosminorStrategic or Co-development PartnerCorporate sponsor of the Pasteur Institute Museum, illustrating collaboration between the institute and the economic world through sponsorship arrangements.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• INSERM: France's national institute for health and medical research jointly operates multiple research units with Institut Pasteur de Lille (UMR1011, UMR1167, UMR1177, UMR1190, UMR1283). It is a broader national incumbent in the same biomedical research domain.
• Karolinska Institutet: Sweden's medical university with deep research portfolio in metabolic disease, neurodegenerative disease, and public health. Comparable in translational research orientation and integration with clinical prevention and population health.
• CNRS: France's national scientific research center co-runs joint research units on the Lille campus (UMR9017, UMR9031, UMR9020) including the cancer and structural biology units. A direct institutional peer in basic biomedical research.
• Howard Hughes Medical Institute: Large US biomedical research organization supporting scientists across many institutions with a focus on discovery science. Comparable as a nonprofit foundation that combines intramural research, talent funding, and translational output.

Direct peers

• Helmholtz Centre for Infection Research (HZI): German research center focused on infectious disease research, antimicrobial resistance, and vaccine development. Directly comparable on the infectious-diseases and antibiotic-resistance research focus of Unit U1019 at Institut Pasteur de Lille.
• The Francis Crick Institute: A large UK biomedical research institute combining discovery science with translational and clinical collaboration. Comparable in scale (~1,500+ scientists), interdisciplinary disease focus, and integration with academic hospital partners.
• Max Planck Institute for Infection Biology: Germany's Max Planck society operates this institute on infection biology and immunology with significant overlap to Institut Pasteur de Lille's immunology, infection, and vaccine research activities.
• Institut Pasteur: The flagship Parisian Pasteur Institute shares the same Pasteur heritage, RIIP membership, public-utility nonprofit status, and integrated research-and-prevention mission. It is the most direct structural and historical peer of Institut Pasteur de Lille.
• Institut Pasteur de Madagascar: Member institute of the same RIIP network delivering research, training, and public health services in a different geography. Shares mission, governance philosophy, and Pasteur brand but focuses on tropical/communicable diseases.

Regional players

• Pasteur Institute of Iran: RIIP network member operating regional public-health, vaccination, and research services. Demonstrates how individual Pasteur institutes adapt the integrated research-plus-prevention model to local disease burdens.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/PasteurLilleTv
• Facebookfacebook.com/pasteurlille
• LinkedInlinkedin.com/company/institut-pasteur-de-lille
• Instagraminstagram.com/pasteur_lille
• Xx.com/pasteurlille

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institut Pasteur de Lille